pocketful logo
Vista Pharmaceuticals Ltd logo

Vista Pharmaceuticals Ltd

NSE: BSE: 524711

₹7.50

(1.63%)

Sun, 22 Mar 2026, 01:46 am

mtf coin illustrationMTF 5x

Vista Pharmaceuticals Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    46.16

  • Net Profit

    -4.65

  • P/B

    1.46

  • Sector P/E

    39.77

  • P/E

    0

  • EV/EBITDA

    0

  • Debt/Equity (Industry)

    0.25

  • Interest Cover (Industry)

    11.42

  • ROCE (Industry)

    16.55

  • RONW (Industry)

    14.50

  • ROE

    0

  • ROCE

    0

  • Debt/Equity

    0.18

  • EPS (TTM)

    0

  • Dividend Yield

    0

  • Book Value

    7.25

  • Interest Cover

    -4.45

Analysis

all

thumbs up icon

Pros

  • Vista Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vista Pharmaceuticals is profitable, therefore cash runway is not a concern.
  • Vista Pharmaceuticals is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (30.4%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 1.7x debt.
thumbs up icon

Cons

  • Unable to evaluate Vista Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vista Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • The level of debt compared to net worth has increased over the past 5 years (0.5% vs 32.4% today).
  • High level of physical assets or inventory.
  • The average tenure for the Vista Pharmaceuticals board of directors is less than 3 years, this suggests a new board.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters21.1921.1921.1921.1921.19
FII00000
DII0.020.020.020.020.02
Public78.7978.7978.7978.7978.79
Government00000

Read More

Technical Analysis

RSI

55.56

MACD

-0.05

50 DMA

7.35

200 DMA

9.24

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic11.189.258.087.326.155.393.46
Fibonacci9.258.528.067.326.596.135.39
Camarilla7.437.257.087.326.726.556.37

Pivots Level: Classic

R3

+3.86

11.18

R2

+1.93

9.25

R1

+0.75

8.08

7.32
7.32
Pivot Point
LTP: 7.50

S1

-1.18

6.15

S2

-1.93

5.39

S3

-3.86

3.46

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    6.95

  • 20-EMA

    6.91

  • 30-EMA

    7.02

  • 50-EMA

    7.30

  • 100-EMA

    7.95

  • 200-EMA

    8.90

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
13 Feb 2026board-meetingsQuarterly Results
13 Nov 2025board-meetingsQuarterly Results
13 Aug 2025agm
19 Feb 2025egm
08 Sept 2024agm
10 Feb 2024egm
11 Sept 2023agm
21 Sept 2022egm
07 Sept 2022agm
02 Sept 2021agm

Read More

Peer Comparison

Vista Pharmaceuticals Ltd logo

Vista Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Lupin Ltd logo

Lupin Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Vista Pharmaceuticals Ltd About

Vista Pharmaceuticals is is engaged in manufacturing and selling of Pharmaceutical, medical and veterinary preparations.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1991

Headquarters

CEO

Dhananjaya Alli

Employees

Contact

Website icon

Website

http://www.vistapharmaceuticals.com

Email icon

Email

admin.hyd@vistapharmaceuticals.com

Phone icon

Phone

91-09291015956

Location icon

Location

Plot No 10to14 16to20 APIIC, Industrial Estate Chotyal, Nalgonda, Telangana,

Read More

Vista Pharmaceuticals Ltd Company History

YearHistory
1991
  • Vista Pharmaceuticals Limited was incorporated under the Companies Act of 1956.
  • The company obtained a Certificate of Commencement of Business.
2003
  • The company issued 352907 fully convertible warrants on a preferential basis to Vista Pharmaceuticals Inc.
  • The company increased its authorised capital from Rs 80 million to Rs 100 million.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
UMAKANTH KATTASell26118813.5412 Jun 2024
SUNDARA RAO BEHTABuy50000013.2910 Jun 2024
UMAKANTH KATTASell75097913.3310 Jun 2024
UMAKANTH KATTASell30010313.2205 Jun 2024
MEHJABEEN SHALAMBuy30000013.2205 Jun 2024
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDSell24466814.4128 Dec 2022
MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITEDBuy18368213.9328 Dec 2022
NAVEEN MALVAYSell2015288.4318 Apr 2022
SURESH GADALEYBuy2637349.3329 Dec 2021
NAVEEN MALVAYBuy20000011.313 Sept 2019

Read More

Vista Pharmaceuticals Ltd News

Vista Pharmaceuticals Reports Q3 FY26 Loss of ₹231.94 Lakhs

Vista Pharmaceuticals posted a net loss of ₹231.94 lakhs for Q3 FY26, widening from ₹132.23 lakhs in Q3 FY25. Revenue declined to ₹241.82 lakhs from ₹255.50 lakhs year-on-year.

13 Feb 2026

co actions results

Vista Pharmaceuticals forms JV with Pleiades Therapeutics

Vista Pharmaceuticals Ltd announces strategic joint venture partnership with Pleiades Therapeutics for end-to-end development of generic and specialty pharmaceutical products for global markets.

03 Feb 2026

co actions results

Vista Pharmaceuticals Reports Widened Loss of Rs 362.21 Lakhs in Q2 FY2025

Vista Pharmaceuticals reported a loss before tax of Rs 362.21 lakhs for the quarter ended September 30, 2025, significantly higher than Rs 125.20 lakhs loss in the corresponding quarter of the previous year, with revenue declining to Rs 165.49 lakhs from Rs 250.17 lakhs. The company recognized a provision for Expected Credit Loss of Rs 205.43 lakhs against long-pending trade receivables and issued 10,249,998 Convertible Share Warrants, receiving Rs 307.50 lakhs as part payment.

13 Nov 2025

earnings

Vista Pharmaceuticals Reports Quarterly Loss, Approves Director Reappointments and AGM Schedule

Vista Pharmaceuticals Limited approved unaudited financial results for the quarter ended June 30, 2025, showing a net loss of Rs. 129.04 lakhs compared to Rs. 85.70 lakhs loss in the same quarter last year. Revenue declined to Rs. 151.88 lakhs from Rs. 179.50 lakhs year-over-year. The board recommended reappointment of two directors retiring by rotation and approved reappointment of three key executives - Managing Director Murali Meraga, and Whole-time Directors Pavan Sathvik Gilaka and Dhananjaya Alli - for three-year terms starting October 19, 2025. The company scheduled its 34th Annual General Meeting for September 30, 2025, via video conferencing, with share transfer books closing from September 24-30, 2025.

13 Aug 2025

earnings

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800